Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peritoneal Dialysis I: Introduction and Procedure01:30

Peritoneal Dialysis I: Introduction and Procedure

5.7K
Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
5.7K
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

1.5K
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
1.5K
Dialysis01:15

Dialysis

2.1K
Dialysis is a diffusion-based purification process that separates analyte molecules from a complex matrix. This is accomplished by allowing molecules in the solution to pass through a semipermeable membrane into a liquid on the other side. The membrane is usually made of cellulose acetate or cellulose nitrate, and the second liquid must be miscible with the solution. Ions (e.g., chloride or sodium) or organic molecules (e.g., glucose) can pass through the membrane pores, which generally have...
2.1K
Dialysis01:27

Dialysis

1.9K
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
1.9K
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

1.3K
Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
1.3K
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis01:30

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

799
Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...
799

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incremental Peritoneal Dialysis.

Advances in kidney disease and health·2025
Same author

Anemia, CKD, and Cognitive Function: The National Health and Nutrition Examination Survey.

Kidney360·2025
Same author

Symptom Burden and Its Impact on Quality of Life in Patients With Moderate to Severe CKD: The International Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps).

American journal of kidney diseases : the official journal of the National Kidney Foundation·2024
Same author

Is there a role for APD in countries with low healthcare resources?

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2024
Same author

Development of PD in lower-income countries: a rational solution for the management of AKI and ESKD.

Kidney international·2024
Same author

Effect of Anemia on Physical Function and Physical Activity in CKD: The National Health and Nutrition Examination Survey, 1999-2016.

Kidney360·2023

Related Experiment Video

Updated: Mar 22, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

16.2K

We Use Bioincompatible Peritoneal Dialysis Solutions.

Laura Troidle1, Joni Hansson1, Peter Juergensen1

  • 1Department of Internal Medicine, Yale University, New Haven, Connecticut.

Seminars in Dialysis
|April 11, 2016
PubMed
Summary
This summary is machine-generated.

Biocompatible peritoneal dialysis (PD) solutions offer benefits for end-stage renal disease (ESRD) patients, including preserved kidney function. Their unavailability in the US hinders PD therapy utilization despite proven advantages.

More Related Videos

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

3.3K
Author Spotlight: Techniques and Challenges in Islet Purification for Xenotransplantation
08:32

Author Spotlight: Techniques and Challenges in Islet Purification for Xenotransplantation

Published on: June 7, 2024

1.9K

Related Experiment Videos

Last Updated: Mar 22, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

16.2K
A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

3.3K
Author Spotlight: Techniques and Challenges in Islet Purification for Xenotransplantation
08:32

Author Spotlight: Techniques and Challenges in Islet Purification for Xenotransplantation

Published on: June 7, 2024

1.9K

Area of Science:

  • Nephrology
  • Renal Replacement Therapy

Background:

  • Peritoneal dialysis (PD) is an underutilized therapy for end-stage renal disease (ESRD) in the United States.
  • Concerns regarding technique failure contribute significantly to the underutilization of PD.
  • Conventional PD solutions have limitations, including higher glucose degradation products and non-neutral pH.

Purpose of the Study:

  • To highlight the underutilization of PD in the US despite technical advances.
  • To discuss the benefits of biocompatible PD solutions available internationally.
  • To advocate for the availability of advanced PD solutions in the United States.

Main Methods:

  • Review of existing literature on PD solutions and their clinical outcomes.
  • Comparison of conventional PD solutions with newer biocompatible alternatives.
  • Analysis of factors contributing to PD underutilization in the US.

Main Results:

  • Biocompatible PD solutions, with lower glucose degradation products and neutral pH, are available globally but not in the US.
  • These solutions demonstrate benefits such as slower decline in residual renal function and better urine volume maintenance.
  • Biocompatible solutions may mitigate the characteristic increase in peritoneal transport seen with conventional solutions.

Conclusions:

  • The lack of access to biocompatible PD solutions in the US is a significant concern for the nephrology community.
  • Wider availability of these advanced solutions could improve PD therapy outcomes and utilization for ESRD patients.
  • Further investigation and policy changes are needed to make biocompatible PD solutions accessible in the United States.